Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.40 USD
-0.04 (-9.26%)
Updated May 15, 2024 03:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Brokerage Reports
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 41 - 60 ( 74 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
SBP-101 Manufacturing Patent Issues in Japan, Expecting Other Geographies
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Shares Do Not Reflect Near-Term Potential & Broad Clinical Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Multiple Value Creation Opportunities, Resuming Coverage With Buy/$10 TP
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Pipeline Updates and Upcoming Milestones
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q22: Final Clinical Data from Phase I in Pancreatic Cancer During 1H2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
R&D Event Highlighted Preclinical Data in Ovarian Cancer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q21: Multiple Events to Look forward to in 2022
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
AACR 2022 Abstract Titles Released: BCYC CRSP GTBP PBLA TCRR
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Pancreatic Cancer Trial Posted on Clinicaltrials.gov
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Acquiring Cancer Prevention Pharmaceuticals for Another Polyamine Inhibitor
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T